Alison Finger

Alison Finger has almost three decades of biotech and pharmaceutical leadership experience building and optimizing brands and portfolios in the areas of Gene Medicine, Cell Therapy, Oncology, Neurology, Virology, and Metabolics. She has commercialized products in the US, EU, Asia, and Globally. Most recently, Alison was Chief Commercial Officer at bluebird bio where she built the commercial business enterprise for Europe and the US and prepared bluebird’s first gene and cell therapy products for the market.

Prior to bluebird, Alison was at Bristol-Myers Squibb leading franchises for Hematology/Oncology, Neurology, and Virology. In these roles, she led portfolio planning, brand, and franchise commercial strategy, and supported R&D and Corporate Business Development decisions. Alison also served as Managing Director of BMS Australia/NZ and has managed country, regional, and global P&Ls. Previously, Alison was chair of the Alliance for Regenerative Medicine Gene Therapy Section and served on the Executive Board of the Alliance for Regenerative Medicine Foundation. She also was a member of the board for The Medicines Australia Industry Association and a member of the Pharmaceutical Strategic Working Group for the Australia Senator for Industry and Innovation. Alison has a B.A. from St. Lawrence University and an M.B.A. from Duke University Fuqua School of Business.